Mutual of America Capital Management LLC Lowers Holdings in Insulet Corporation $PODD

Mutual of America Capital Management LLC decreased its holdings in Insulet Corporation (NASDAQ:PODD) by 1.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,074 shares of the medical instruments supplier’s stock after selling 89 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Insulet were worth $2,851,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Inspire Investing LLC boosted its stake in shares of Insulet by 299.5% in the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 3,088 shares during the period. Gradient Investments LLC purchased a new position in Insulet in the second quarter worth approximately $17,429,000. Goldman Sachs Group Inc. lifted its stake in Insulet by 1.9% in the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock worth $152,130,000 after acquiring an additional 10,628 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Insulet by 55.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier’s stock worth $1,376,000 after acquiring an additional 1,867 shares during the last quarter. Finally, Vident Advisory LLC purchased a new position in Insulet in the first quarter worth approximately $216,000.

Analysts Set New Price Targets

PODD has been the subject of a number of recent research reports. Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Citigroup reiterated a “buy” rating on shares of Insulet in a research note on Tuesday, July 8th. Zacks Research upgraded shares of Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Barclays lifted their price target on shares of Insulet from $266.00 to $300.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. Finally, Rothschild & Co Redburn lifted their price target on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $352.11.

Insiders Place Their Bets

In other news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Insulet Stock Down 0.8%

PODD stock opened at $320.91 on Friday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet Corporation has a twelve month low of $226.50 and a twelve month high of $353.50. The company’s 50 day moving average is $327.60 and its two-hundred day moving average is $304.43. The stock has a market cap of $22.59 billion, a P/E ratio of 97.54, a PEG ratio of 2.70 and a beta of 1.40.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s revenue for the quarter was up 32.9% on a year-over-year basis. During the same quarter last year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.